Search Results - immunotherapy

10 Results
Sort By:

Cholesterol Analogues Incorporated Into LNPs For Enhanced mRNA Delivery

Hydroxycholesterols are used to formulate lipid nanoparticles (LNPs) for enhanced mRNA delivery into T cells.

Published: 2/6/2024
Inventor(s):
Michael Mitchell, Margaret Billingsley, Savan Patel, Xuexiang Han, Hanwen Zhang
Keywords(s):
Bioengineering, Cell Therapy, Drug Delivery, Gene Editing, Gene Therapy, Genetic Disorders, Immunology, Immunoncology, Immunotherapy, Inflammation, Nanotechnology, Platform Technology
Category(s):
Technology Classifications > Therapeutics

Compositions and methods for enhancing the anti-tumor activity of CAR T cells by co-expression of CH25H

Co-expression of modified chimeric antigen receptor (CAR) T cells and cholesterol 25-hydroxylase (CH25H) in a single construct for treatment of solid tumor and hematological cancers. 

Published: 1/23/2024
Inventor(s):
Serge Fuchs, Noreen McBrearty, Zhen Lu
Keywords(s):
Bioengineering, CAR T-cell Enhancing Technology, Cell Therapy, Immunoncology, Immunotherapy, Oncology, Platform Technology
Category(s):
Technology Classifications > Therapeutics

CD137 enrichment of tumor-specific tumor-infiltrating lymphocytes (TILs)

A platform to isolate and expand CD137-positive (CD137pos) tumor-infiltrating lymphocytes (TILs) to use in adoptive immunotherapy and translational studies.

Published: 4/2/2024
Inventor(s):
Daniel Powell
Keywords(s):
CAR T-cell Enhancing Technology, Cell Therapy, Immunology, Immunoncology, Immunotherapy, Oncology, Platform Technology
Category(s):
Technology Classifications > Research Tools & Reagents, Technology Classifications > Therapeutics, Technology Classifications > Vaccines

Adoptive T cell therapy for cancer using Mutant KRAS-specific T cell receptors for T cell engineering

We have isolated, cloned, and characterized multiple T cell receptors (TCRs) from human donors specific for common mutations in KRAS and restricted to highly prevalent HLA types.  These TCRs, protected by a Penn provisional filing, are suitable for T cell engineering for the adoptive immunotherapy of cancer patients of select HLA types and tumors expressing particular KRAS mutantions.

The comprehensive bioinformatics, biochemical and immunological assessment of these TCRs is in press (Bear et al, Nature Communications).

Published: 10/16/2023
Inventor(s):
Adham Bear, Robert Vonderheide, Gerald Linette, Beatriz Carreno
Keywords(s):
Cell Therapy, Immunology, Immunotherapy, Oncology
Category(s):
Technology Classifications > Therapeutics

Lipid nanoparticle-based mRNA delivery for CAR T-cell engineering

A library of ionizable lipid nanoparticles (LNPs) was screened for ability to deliver mRNA to T-cells, leading to an optimized LNP formulation for delivery of mRNA to T-cells. This thereby enhances the ability to generate transient chimeric antigen receptor (CAR)-expressing T-cells for cancer immunotherapy.

Published: 1/23/2024
Inventor(s):
Margaret Billingsley, Carl June, Nathan Singh, Michael Mitchell
Keywords(s):
Bioengineering, COVID-19, Drug Delivery, Immunology, Immunotherapy
Category(s):
Technology Classifications > Therapeutics

Total synthesis of tamandarin and didemnin analogs for development of cancer therapeutics and immunosuppressive therapies

Preparation of macrocyclic derivatives of tamandarin and evaluation of biological activity

Published: 1/5/2024
Inventor(s):
Madeleine Joullie
Keywords(s):
Immunotherapy, Oncology
Category(s):
Technology Classifications > Chemical Processes and Synthesis, Technology Classifications > Therapeutics

Selective phagocytosis of human cancer cells as target for immunotherapy

Cell therapy based methods to reduce tumor growth by disrupting the CD47-SIRPα interaction and targeting cells for phagocytosis with antibodies.

Published: 10/16/2023
Inventor(s):
Dennis Discher
Keywords(s):
Immunotherapy, Oncology
Category(s):
Technology Classifications > Medical Devices, Technology Classifications > Therapeutics

Targeting the Retinoic Acid Pathway to Bolster Immunotherapy

A strategy to increase the effect of immune checkpoint blockade by targeting retinoic acid signaling in immunosuppressive solid tumors.

Published: 1/11/2024
Inventor(s):
Malay Haldar, Samirkumar Devalaraja
Keywords(s):
Immunotherapy
Category(s):
Technology Classifications > Therapeutics

Enhancing the Efficacy of Tumor Immunotherapy by Targeting Endothelin Receptor B

Antagonism of Endothelin Receptor B (ETRB) increases intratumoral T cell homing to tumors and enables tumor response to otherwise ineffective immunotherapy

Published: 1/10/2024
Inventor(s):
George Coukos
Keywords(s):
Immunotherapy, Oncology
Category(s):
Technology Classifications > Vaccines

Immunotoxin therapeutic targets epithelial derived cancers

Immunotoxin chimeras of DNaseI and cytolethal distending toxin (CdtB subunit) are an effective therapeutic against epithelial tumors. 

Published: 10/16/2023
Inventor(s):
Joseph Dirienzo
Keywords(s):
Immunotherapy, Oncology
Category(s):
Technology Classifications > Therapeutics